Table 3. Total cell number of CD4 T cells subsets gated according to the effector/memory CD45RO and CD26 staining and CD26 cell surface level (MFI) in RA patients undergoing different therapies.
| No BT (n = 21) | Anti-TNFα BT (n = 47) | Anti-CD20 BT (n = 10) | Anti-IL6R/Ig-CTLA4 BT (n = 13) | |||||
|---|---|---|---|---|---|---|---|---|
| (x 109 cel L-1) | Mean ± SD | CI (95%) | Mean ± SD | CI (95%) | Mean ± SD | CI (95%) | Mean ± SD | CI (95%) |
| Lymphocytes | 2.11 ± 0.94 | 1.71–2.53 | 2.73 ± 0.98* # | 2.47–2.99 | 2.06 ± 0.8** | 1.6–2.53 | 2.47 ± 0.54** | 2.01–2.62 |
| CD3+ CD4+ | 0.99 ± 0.45 | 0.78–1.2 | 1.26 ± 0.51* | 1.12–1.41 | 1.12 ± 0.42 | 0.82–1.42 | 1.12 ± 0.28 | 0.95–1.29 |
| CD26+ in CD4 | 0.72 ± 0.35 | 0.57–0.89 | 0.97 ± 0.43* | 0.84–1.1 | 0.96 ± 0.38 | 0.69–1.23 | 0.79 ± 0.32 | 0.6–0.98 |
| CD45RO+ in CD4 | 0.46 ± 0.26 | 0.34–0.58 | 0.57 ± 0.25 | 0.5–0.64 | 0.45 ± 0.13 | 0.36–0.64 | 0.47 ± 0.15 | 0.38–0.57 |
| CD45RO-CD26+ in CD4 | 0.4 ± 0.24 | 0.29–0.51 | 0.56 ± 0.35 | 0.46–0.67 | 0.6 ± 0.31 | 0.38–0.82 | 0.51 ± 0.22 | 0.38–0.65 |
| CD45RO+CD26- in CD4 | 0.13 ± 0.11 | 0.08–0.18 | 0.16 ± 0.11 | 0.13–0.2 | 0.09 ± 0.05** | 0.06–0.13 | 0.14 ± 0.9 | 0.08–0.19 |
| CD45RO+CD26+ in CD4 | 0.22 ± 0.11 | 0.18–0.27 | 0.3 ± 0.13* | 0.26–0.34 | 0.25 ± 0.07 | 0.19–0.3 | 0.23 ± 0.08 | 0.24–0.29 |
| CD45RO+CD26++ in CD4 | 0.11 ± 0.11 | 0.05–0.16 | 0.11 ± 0.06 | 0.09–0.13 | O.11 ± 0.07 | 0.06–0.16 | 0.1 ± 0.1 | 0.04–0.13 |
n = number of samples; CI = confidence interval; SD = standard deviation; BT = biological therapy
*Values significantly different to No BT group at p < 0.05 (Student´s t-test)
** Values significantly different to anti-TNFα group at p < 0.05 (Student´s t-test)
# Values significantly different to control group (No BT) at p < 0.05 (Dunnett´s t-test)